BNGO vs. CLIR, OPTX, OWLT, RPID, OMIC, MSAI, AATC, OPXS, DAIO, and AXDX
Should you be buying Bionano Genomics stock or one of its competitors? The main competitors of Bionano Genomics include ClearSign Technologies (CLIR), Syntec Optics (OPTX), Owlet (OWLT), Rapid Micro Biosystems (RPID), Singular Genomics Systems (OMIC), MultiSensor AI (MSAI), Autoscope Technologies (AATC), Optex Systems (OPXS), Data I/O (DAIO), and Accelerate Diagnostics (AXDX). These companies are all part of the "measuring and control equipment" industry.
Bionano Genomics vs.
ClearSign Technologies (NASDAQ:CLIR) and Bionano Genomics (NASDAQ:BNGO) are both small-cap industrial products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
Bionano Genomics received 10 more outperform votes than ClearSign Technologies when rated by MarketBeat users. Likewise, 64.03% of users gave Bionano Genomics an outperform vote while only 42.34% of users gave ClearSign Technologies an outperform vote.
ClearSign Technologies has a net margin of -118.93% compared to Bionano Genomics' net margin of -407.34%. ClearSign Technologies' return on equity of -50.44% beat Bionano Genomics' return on equity.
ClearSign Technologies has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Bionano Genomics has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500.
ClearSign Technologies has higher earnings, but lower revenue than Bionano Genomics. ClearSign Technologies is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.
24.0% of ClearSign Technologies shares are owned by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are owned by institutional investors. 16.9% of ClearSign Technologies shares are owned by company insiders. Comparatively, 1.6% of Bionano Genomics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
ClearSign Technologies currently has a consensus price target of $6.00, suggesting a potential upside of 334.78%. Bionano Genomics has a consensus price target of $1.50, suggesting a potential upside of 732.87%. Given Bionano Genomics' higher possible upside, analysts plainly believe Bionano Genomics is more favorable than ClearSign Technologies.
In the previous week, ClearSign Technologies and ClearSign Technologies both had 1 articles in the media. ClearSign Technologies' average media sentiment score of 0.00 beat Bionano Genomics' score of -0.16 indicating that ClearSign Technologies is being referred to more favorably in the media.
Summary
ClearSign Technologies beats Bionano Genomics on 11 of the 17 factors compared between the two stocks.
Get Bionano Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bionano Genomics Competitors List
Related Companies and Tools
This page (NASDAQ:BNGO) was last updated on 1/22/2025 by MarketBeat.com Staff
